<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1002" relname="joint">Early diagnosis and treatment of human malaria reduces disease , prevents deaths ,</segment>
<segment id="3" parent="1002" relname="joint">and contributes to reduced transmission .</segment>
<segment id="4" parent="1004" relname="span">Detection of antibody response against malaria antigens is often done through Enzyme-Linked Immunosorbent Assay</segment>
<segment id="5" parent="4" relname="restatement">( ELISA ) ;</segment>
<segment id="6" parent="1007" relname="span">many of these diagnostic assays are designed with a single antigen or with recombinant antigens of different stages of the parasites</segment>
<segment id="7" parent="6" relname="elaboration">( tissue infection or blood ) ,</segment>
<segment id="8" parent="1008" relname="joint">where merozoite surface proteins can be detected ,</segment>
<segment id="9" parent="1008" relname="joint">and have demonstrated good sensitivity and specificity .</segment>
<segment id="10" parent="1010" relname="same_unit">However , many individuals cannot be easily diagnosed</segment>
<segment id="11" parent="1010" relname="same_unit">due to the low levels of antibodies present in their blood .</segment>
<segment id="12" parent="1012" relname="span">In this context , the use of ELISA as a tool for laboratory diagnosis of malaria has some limitations ,</segment>
<segment id="13" parent="1014" relname="span">namely :</segment>
<segment id="14" parent="13" relname="restatement">( i )</segment>
<segment id="15" parent="1017" relname="span">low antibody titres</segment>
<segment id="16" parent="15" relname="elaboration">presented by individuals in the acute phase of infection ;</segment>
<segment id="17" parent="1017" relname="restatement">( ii )</segment>
<segment id="18" parent="1019" relname="span">many Plasmodium sp . are involved in human malaria ;</segment>
<segment id="19" parent="18" relname="restatement">( iii )</segment>
<segment id="20" parent="1020" relname="joint">different evolutionary forms of Plasmodium spp. during infection and life cycle ;</segment>
<segment id="21" parent="1021" relname="same_unit">and ( iv )</segment>
<segment id="22" parent="1021" relname="same_unit">different resistance and susceptibility profiles during infection , and consequently in the immunity profile against malaria parasites .</segment>
<segment id="23" parent="1023" relname="span">Associations among antibodies against parasite antigens and malaria risk areas are not always consistent ;</segment>
<segment id="24" parent="1024" relname="contrast">some may depend on parasite antigens</segment>
<segment id="25" parent="1024" relname="contrast">and other considerations may be due to the endemic areas of malaria .</segment>
<segment id="26" parent="27" relname="attribution">It should be considered</segment>
<segment id="27" parent="1029" relname="span">that single responses of antibodies against antigens might be inadequate to for use as biomarkers and indicators of malaria transmission intensity .</segment>
<segment id="28" parent="29" relname="attribution">Other authors have shown</segment>
<segment id="29" parent="1030" relname="span">that new serological biomarkers can more accurately estimate the recent exposure to P. falciparum not only of a community , but also for several communities .</segment>
<segment id="30" parent="1028" relname="elaboration">In 2015 , approximately 3.2 billion people — nearly half of the world ’s population — were at risk of malaria , mainly by P. falciparum .</segment>
<segment id="31" parent="1031" relname="span">After several decades of disease control campaigns , malaria persists as one of the most serious public health problems , not only in endemic countries , but also in non-endemic regions ,</segment>
<segment id="32" parent="31" relname="elaboration">where the number of cases of imported malaria via tourists and immigrants is on the rise .</segment>
<segment id="33" parent="1035" relname="span">P. falciparum is one the most lethal species of the malaria parasites</segment>
<segment id="34" parent="33" relname="elaboration">that infect humans ,</segment>
<segment id="35" parent="1036" relname="span">and is responsible for the highest number of serious pathologies</segment>
<segment id="36" parent="35" relname="elaboration">associated with the disease .</segment>
<segment id="37" parent="1038" relname="span">In this work , we performed a comparative analysis of the serological reactivity of total antimalarial antibodies</segment>
<segment id="38" parent="37" relname="elaboration">obtained by a commercial ELISA</segment>
<segment id="39" parent="1039" relname="span">using recombinant antigens from Plasmodium sp . ,</segment>
<segment id="40" parent="1040" relname="span">compared to an in-house ELISA ,</segment>
<segment id="41" parent="40" relname="means">using crude extract of P. falciparum 3D7 .</segment>
<segment id="42" parent="1042" relname="attribution">Thus , we showed</segment>
<segment id="43" parent="1042" relname="span">that several other P. falciparum antigens are equally important for the serological diagnosis of malaria , as well as some recombinant antigens</segment>
<segment id="44" parent="43" relname="elaboration">commonly used in commercial ELISA .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1003" relname="preparation"/>
<group id="1003" type="span" parent="1001" relname="span"/>
<group id="1004" type="span" parent="1005" relname="preparation"/>
<group id="1005" type="span" parent="1003" relname="span"/>
<group id="1006" type="span" parent="1009" relname="background"/>
<group id="1007" type="span" parent="1006" relname="span"/>
<group id="1008" type="multinuc" parent="1007" relname="elaboration"/>
<group id="1009" type="span" parent="1005" relname="span"/>
<group id="1010" type="multinuc" parent="1011" relname="preparation"/>
<group id="1011" type="multinuc" parent="1009" relname="span"/>
<group id="1012" type="span" parent="1011" relname="joint"/>
<group id="1013" type="multinuc" parent="12" relname="elaboration"/>
<group id="1014" type="span" parent="1013" relname="same_unit"/>
<group id="1015" type="multinuc" parent="1013" relname="same_unit"/>
<group id="1016" type="span" parent="1015" relname="same_unit"/>
<group id="1017" type="span" parent="1016" relname="span"/>
<group id="1018" type="multinuc" parent="1015" relname="same_unit"/>
<group id="1019" type="span" parent="1018" relname="same_unit"/>
<group id="1020" type="multinuc" parent="1018" relname="same_unit"/>
<group id="1021" type="multinuc" parent="1020" relname="joint"/>
<group id="1023" type="span" parent="1011" relname="joint"/>
<group id="1024" type="multinuc" parent="23" relname="elaboration"/>
<group id="1026" type="span" parent="1011" relname="joint"/>
<group id="1027" type="span" parent="1026" relname="span"/>
<group id="1028" type="span" parent="1027" relname="span"/>
<group id="1029" type="span" parent="1028" relname="span"/>
<group id="1030" type="span" parent="1029" relname="elaboration"/>
<group id="1031" type="span" parent="1027" relname="elaboration"/>
<group id="1032" type="span" parent="1011" relname="joint"/>
<group id="1033" type="span" parent="1032" relname="span"/>
<group id="1034" type="multinuc" parent="1033" relname="span"/>
<group id="1035" type="span" parent="1034" relname="joint"/>
<group id="1036" type="span" parent="1034" relname="joint"/>
<group id="1037" type="span" parent="1034" relname="elaboration"/>
<group id="1038" type="span" parent="1037" relname="span"/>
<group id="1039" type="span" parent="1038" relname="means"/>
<group id="1040" type="span" parent="39" relname="concession"/>
<group id="1041" type="span" parent="1033" relname="elaboration"/>
<group id="1042" type="span" parent="1041" relname="span"/>
	</body>
</rst>
